REFERENCES
- Dore GJ, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13(10):1249–1253.
- Becker JT, et al. Prevalence of cognitive disorders dif-fers as a function of age in HIV virus infection. AIDS. 2004;18(Suppl 1):S11–18.
- Joska JA, et al. Characterization of HIV-associated neuro-cognitive disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav. 2011;15(6): 1197–1203.
- Ryan EL, et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. 2004;62(6):957–962.
- Thiyagarajan A, et al. Cerebral function tests reveal differ-ences in HIV-infected subjects with and without chronic HCV co-infection. Clin Microbiol Infect. 2010;16(10): 1579–1584.
- Letendre S, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral pene-tration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
- Heaton RK, et al. The impact of HIV-associated neuro-psychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10(3):317–331.
- Sacktor N, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology. 2001;56 (2):257–260.
- Bhaskaran K, et al. Changes in the incidence and predic-tors of human immunodeficiency virus-associated demen-tia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213–221.
- Wright E, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008;71(1):50–56.
- Heaton RK, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHAR-TER Study. Neurology. 2010;75(23):2087–2096.
- Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the con-text of plasma HIV RNA suppression. J Neurovirol. 2011;17(2)1 76–183.
- Letendre S, et al. Correlates of CSF viral loads in 1221 volunteers in the CHARTER Cohort. Presented at: Seventeenth Conference on Retroviruses and Opportunis-tic Infections; 2010; San Francisco, CA.
- Cysique LA, et al. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21(2):185–194.
- Winston A, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individu-als commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6):920–929.
- Sacktor NC, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19(13):1367–1374.
- Antinori A, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
- Stanton DL, et al. Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr. 1994;7(10):1050–1056.
- Gonzalez R, et al. Computerized reaction time battery versus a traditional neuropsychological battery: detect-ing HIV-related impairments. J Int Neuropsychol Soc. 2003;9(1):64–71.